In light of the recent concerns surrounding testosterone therapy, as well as the allegations raised in testosterone lawsuits involving AndroGel, it would seem that the stance taken by the Endocrine Society is a prudent one.
New York, NY (PRWEB) February 10, 2014
As testosterone treatment lawsuits (http://www.testosteronelawsuitcenter.com/)
alleging serious heart injuries due to the use of AndroGel mount in courts around the country, Bernstein Liebhard LLP notes that the Endocrine Society has issued a new statement calling for large-scale studies to evaluate the risks potentially associated with prescription testosterone therapy medications. According to the group, the February 7th statement was prompted by the publication of two retrospective analysis and one randomized trial that found a high rate of serious cardiovascular events in men with preexisting heart problems who received testosterone. Among other things, the Society maintains that more large-scale randomized controlled trials are needed to determine the true risks and benefits of testosterone therapy in older men.*
“In light of the recent concerns surrounding testosterone therapy, as well as the allegations raised in testosterone lawsuits involving AndroGel, it would seem that the stance taken by the Endocrine Society is a prudent one,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free legal reviews to anyone who may have suffered serious heart attacks, strokes, deep vein thrombosis or pulmonary embolism, allegedly due to the use of prescription testosterone therapies.
Prescription testosterone therapies are approved to treat low testosterone in men who suffer from the condition as a result of an associated medical disorder. Drugs in this class include:
- Bio-T Gel
As the Endocrine Society points out, these drugs are not approved to treat age-related symptoms or the age-related decline of testosterone levels.
On January 31, 2014, the U.S. Food & Drug Administration (FDA) announced a safety review of prescription testosterone treatments, which was prompted by the publication of two of the studies cited by the Endocrine Society. The FDA has not yet concluded that these drugs will raise the risk of serious heart events in some men, but has advised doctors to weigh their risk and benefits when they are prescribed.
Since the FDA announced its review, four AndroGel lawsuits have been filed in the U.S. District Court, Northern District of Illinois by men who allegedly suffered serious heart events due to their use of the medication. Among other things, the complaints allege that the manufacturer of AndroGel created demand for the drug via marketing materials that prompted men to seek testosterone therapy for fatigue, low libido, and other problems associated with the normal aging process. As a result, the lawsuits claim that drugs like AndroGel are often prescribed to men who have normal testosterone levels. (Case Nos: 1:14-cv-00776, 1:14-cv-00780, 1:14-cv-00777, and 1:14-cv-00772)
Victims of heart attacks, strokes, deep vein thrombosis and pulmonary embolism allegedly associated with the use of AndroGel or similar drugs may be entitled to file a testosterone treatment lawsuit seeking compensation for their injury-related damages. To learn more about filing a testosterone lawsuit, please visit Bernstein Liebhard LLP’s website. Free, no-obligation legal consultations can be obtained by calling 800-511-5092.
*endocrine.org/~/media/endosociety/Files/Advocacy%20and%20Outreach/Position%20Statements/Other%20Statements/The%20Risk%20of%20Cardiovascular%20Events%20in%20Men%20Receiving%20Testosterone%20Therapy.pdf; Endocrine Society, February 7, 2014
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 11 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com